Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects With Hyperlipidemia or Mixed Dyslipidemia at Risk of Cardiovascular Events
NCT01968967
·
clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
2139
Enrollment
INDUSTRY
Sponsor class
Conditions
Hyperlipidemia
Interventions
DRUG:
Bococizumab (PF-04950615; RN316)
OTHER:
Placebo
Sponsor
Pfizer